Boston, MA 10/15/2014 (wallstreetpr) – Acasti Pharma Inc. (NASDAQ:ACST) is a renowned biopharmaceutical company that focuses on research and development of omega-3 oil based therapies which treat and prevent some cardiometabolic disorders. The company is also engaged in the commercialization of omega-3 oil based therapies. The company recently announced its results for over 3.5 years which ended on August 31, 2014.
Positive Results
The Interim President and CEO, Andre Godin, says that Acasti Pharma Inc. (NASDAQ:ACST) put its efforts to progress or develop the drug to get necessary approvals for proper regulation, distribution and marketing of the drug CaPre(R). Recently, the company also announced positive and good clinical results for both Pharmacokinetic (PK) trials and Phase II double-blind TRIFECTA trials. The biggest positive feedback for the company is that its drug CaPre(R) was shown as the most effective and safe drug in treating hypertriglyceridemia patients.
Additionally, CaPre(R) resulted into a good improvement in decreasing non-HDL-C that causes cardiovascular disease and triglycerides (TG). At the same time, Capre(R) didn’t increase further levels of bad cholesterol i.e. LDL-C but increased the level of good cholesterol i.e. HDL-C. The drug further indicated a significant reduction in VLDL-C, which is known as prime indicator of causing a coronary artery disease. The PK study also confirmed that CaPre(R) has bioavailability which was not affected by the fat component of any meal. This important finding can become a part of a low-fat diet given to hypertriglyceridemic patients.
Poor Results
It can be assumed that CaPre(R) has helped the company in achieving good will in the industry. Acasti Pharma Inc. (NASDAQ:ACST) had total revenues of $8000 for the 2nd quarter that ended as on August 31, 2014. The Research & Development expenses were $1803000 which also increased as the same was $1526000 last year. The net loss was $(3712000) for the quarter which was again more than that of last year, which was $(3238000). The company hopes to improve this with its further positive clinical trials.
